Cacciapuoti, A., Loebenberg, D., Corcoran, E., Menzel Jr., F., Moss Jr., E.L., Norris, C., Michalski, M., Raynor, K., Halpern, J., Mendrick, C., Arnold, B., Antonacci, B., Parmegiani, R., Yarosh-Tomaine, T., Miller, G.H. and Hare, R.S. (2000) In Vitro and in Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida. Antimicrobial Agents and Chemotherapy, 44, 2017-2022.
http://www.ncbi.nlm.nih.gov/pubmed/10898669
https://doi.org/10.1128/AAC.44.8.2017-2022.2000

has been cited by the following article:

• TITLE: Analysis of Pharmacokinetic/Pharmacodynamic Parameters and Dosage Regimen of Posaconazole against Candida spp. and Aspergillus spp. Using Monte Carlo Simulation

  AUTHORS: Ying Wang, Jingyi Zhao, Junhui Hu, Xinhong Zhao, Yinhui Yao

  KEYWORDS: Posaconazole, Monte Carlo Simulation, Candida spp., Aspergillus spp., Pharmacokinetics/Pharmacodynamics

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.11 No.1, January 17, 2020

  ABSTRACT: Invasive fungal infections (IFI) have recently become increasingly more prevalent, resulting in an increased risk of morbidity and mortality. Both Candida spp. and Aspergillus spp. are major causes of IFI. In this study, we aimed to evaluate the cumulative fraction of response of various dosage regimens of posaconazole against nine Candida spp. and six Aspergillus spp. in both children and adults. Monte Carlo simulation (MCS) was performed to optimize selection of posaconazole dosage regimens. For children, a dosage regimen of 120 mg/m2 posaconazole tid was sufficient to treat fungal infections caused by all six Aspergillus spp. and six of the nine Candida spp. (but was not effective against C. glabrata, C. guilliermondii and C. krusei). In contrast, a 400 mg dosage regimen of posaconazole bid achieved the target pharmacokinetic/pharmacodynamics (PK/PD) parameters against all six Aspergillus spp. and eight of the nine Candida spp. (but was not effective against C. glabrata) in the adults. Dosage regimens of 50 mg bid, 100 mg bid, or 200 mg bid were not effective. Posaconazole dosage regimens are likely to achieve their desired PK/PD targets against Candida spp. and Aspergillus spp. in both children and adults.